PET with 18F-FDG is the standard modality in nuclear medicine for imaging multiple myeloma (MM). However, viable MM as detected by MRI or PET with other metabolic tracers, including 11C-methionine, may be missed-for example, because of low hexokinase 2 (HK2) expression of tumor cells. The aim of this study was to further investigate potential reasons for PET false negativity. Methods: A cohort of 15 mainly pretreated patients with relapsed or refractory biopsy-proven, serologically active MM who underwent both 18F-FDG and 11C-methionine PET/CT was retrospectively analyzed. Results: In 9 of the 15 patients, 18F-FDG PET was negative in the presence of viable disease. In the remaining 6 patients, both 18F-FDG and 11C-methionine PET/CT revealed the same number of MM lesions. At immunohistochemistry, 18F-FDG-negative myeloma did not exhibit significant differences in HK2 or glucose-6-phosphatase expression from 18F-FDG-positive disease (P = 0.57 and P = 0.44, respectively). Conclusion: Beyond HK2 expression, 18F-FDG negativity in (mainly pretreated) MM patients seems to be associated with additional causes not yet known.
PET with 18F-FDG is the standard modality in nuclear medicine for imaging multiple myeloma (MM). However, viable MM as detected by MRI or PET with other metabolic tracers, including 11C-methionine, may be missed-for example, because of low hexokinase 2 (HK2) expression of tumor cells. The aim of this study was to further investigate potential reasons for PET false negativity. Methods: A cohort of 15 mainly pretreated patients with relapsed or refractory biopsy-proven, serologically active MM who underwent both 18F-FDG and 11C-methionine PET/CT was retrospectively analyzed. Results: In 9 of the 15 patients, 18F-FDG PET was negative in the presence of viable disease. In the remaining 6 patients, both 18F-FDG and 11C-methionine PET/CT revealed the same number of MM lesions. At immunohistochemistry, 18F-FDG-negative myeloma did not exhibit significant differences in HK2 or glucose-6-phosphatase expression from 18F-FDG-positive disease (P = 0.57 and P = 0.44, respectively). Conclusion: Beyond HK2 expression, 18F-FDG negativity in (mainly pretreated) MMpatients seems to be associated with additional causes not yet known.
Authors: A Paschali; E Panagiotidis; T Triantafyllou; V Palaska; K Tsirou; E Verrou; E Υiannaki; D Markala; A Papanikolaou; A Pouli; P Konstantinidou; V Chatzipavlidou; E Terpos; E Katodritou Journal: Eur J Nucl Med Mol Imaging Date: 2020-10-25 Impact factor: 9.236
Authors: Antonio Giovanni Solimando; Matteo Claudio Da Vià; Sebastiano Cicco; Patrizia Leone; Giuseppe Di Lernia; Donato Giannico; Vanessa Desantis; Maria Antonia Frassanito; Arcangelo Morizio; Julia Delgado Tascon; Assunta Melaccio; Ilaria Saltarella; Giuseppe Ranieri; Roberto Ria; Leo Rasche; K Martin Kortüm; Andreas Beilhack; Vito Racanelli; Angelo Vacca; Hermann Einsele Journal: J Clin Med Date: 2019-07-09 Impact factor: 4.241
Authors: Marius E Mayerhoefer; Stephen J Archibald; Christina Messiou; Anton Staudenherz; Dominik Berzaczy; Heiko Schöder Journal: J Magn Reson Imaging Date: 2019-07-01 Impact factor: 4.813
Authors: Frederic E Lecouvet; Marie-Christiane Vekemans; Thomas Van Den Berghe; Koenraad Verstraete; Thomas Kirchgesner; Souad Acid; Jacques Malghem; Joris Wuts; Jens Hillengass; Vincent Vandecaveye; François Jamar; Olivier Gheysens; Bruno C Vande Berg Journal: Skeletal Radiol Date: 2021-08-07 Impact factor: 2.199